Chen Ran, Gong Kai, Chen Wei, Chen Zongfeng, Hua Xiang, Tan Jiaxin, Tian Yu, Liu Dong, Zhang Lianyang, Tang Ying, Li Yang, Zhou Siru
War Trauma Medical Center, State Key Laboratory of Trauma and Chemical Poisoning, Army Medical Center, Daping Hospital, Army Medical University, Chongqing, 400042, P. R. China.
Department of Orthopaedics, The First Affiliated Hospital of Chengdu Medical College, Sichuan Province, Chengdu, 610500, P. R. China.
Osteoporos Int. 2025 Feb;36(2):283-297. doi: 10.1007/s00198-024-07324-w. Epub 2024 Nov 29.
This study examined the association of serum total alkaline phosphatase (T-ALP) with bone mineral density (BMD) and osteoporosis prevalence in the general population, and investigated its association with mortality in individuals with osteoporosis, using data from the National Health and Nutrition Examination Survey (NHANES) between 2005 and 2018. Elevated serum T-ALP levels were significantly associated with both reduced BMD and an increased risk of osteoporosis in all participants. Moreover, elevated T-ALP levels were linked to higher all-cause mortality among individuals with osteoporosis during this period.
The evidence regarding the association between serum T-ALP, BMD and osteoporosis prevalence in general population is incomplete, and limited evidence is available concerning its association with mortality among individuals with osteoporosis. The study investigated the association of serum T-ALP with BMD and osteoporosis prevalence in the general population, and examined its association with mortality in individuals with osteoporosis.
All participants were adults from the NHANES (2005-2018), and mortality data were obtained from the National Death Index up to December 31, 2019. Firstly, the association of serum T-ALP with BMD and osteoporosis risk was assessed using linear regression model, subgroup analysis, analysis of covariance and weighted logistic regression model, respectively. Secondly, survival analysis including Kaplan-Meier curves, Cox proportional hazards models, and restricted cubic spline regression models were utilized to analyze the relationship between serum T-ALP levels and mortality risk.
The study included 13,724 participants aged 18 to 85 years, and 944 were diagnosed with osteoporosis, among whom 221 died during a median of 133 months follow-up. Totally, elevated serum T-ALP was significantly associated with low BMD in femoral neck and lumbar spine, and the results exhibited consistency across diverse age, genders, races, and BMI subgroups. Moreover, for each 1 SD increase in T-ALP, there was a 0.5% increase in the prevalence of osteoporosis [OR (95%CI): 1.005 (1.005, 1.005), p < 0.001]. Among individuals with osteoporosis, for every 1 SD increase in T-ALP, the all-cause mortality increased by 0.4% [HR (95%CI):1.004 (1.002, 1.006), p < 0.001]. Meanwhile, comparing participants with highest serum T-ALP levels (> 79 IU/L) to those with lowest levels (< 53 IU/L) further raised the prevalence of osteoporosis [OR (95%CI):1.292 (1.021, 1.636), p = 0.033] and all-cause mortality [HR (95% CI):1.232 (1.041, 1.459), p = 0.015].
Based on a representative sample of US adults, elevated serum T-ALP levels were found to be significantly associated with both reduced BMD and an increased risk of osteoporosis across all participants, as well as with a higher all-cause mortality in individuals with osteoporosis.
本研究利用2005年至2018年美国国家健康与营养检查调查(NHANES)的数据,考察了普通人群中血清总碱性磷酸酶(T-ALP)与骨密度(BMD)及骨质疏松症患病率之间的关联,并研究了其与骨质疏松症患者死亡率之间的关联。在所有参与者中,血清T-ALP水平升高与骨密度降低和骨质疏松症风险增加均显著相关。此外,在此期间,T-ALP水平升高与骨质疏松症患者的全因死亡率较高有关。
关于普通人群中血清T-ALP、骨密度和骨质疏松症患病率之间关联的证据并不完整,关于其与骨质疏松症患者死亡率之间关联的证据有限。本研究调查了普通人群中血清T-ALP与骨密度及骨质疏松症患病率之间的关联,并考察了其与骨质疏松症患者死亡率之间 的关联。
所有参与者均为NHANES(2005 - 2018年)中的成年人,死亡率数据来自截至2019年12月31日的国家死亡指数。首先,分别使用线性回归模型、亚组分析、协方差分析和加权逻辑回归模型评估血清T-ALP与骨密度及骨质疏松症风险之间的关联。其次,采用包括Kaplan-Meier曲线、Cox比例风险模型和受限立方样条回归模型在内的生存分析来分析血清T-ALP水平与死亡风险之间的关系。
该研究纳入了13724名年龄在18至85岁之间的参与者,其中944人被诊断为骨质疏松症,在中位随访133个月期间,有221人死亡。总体而言,血清T-ALP升高与股骨颈和腰椎骨密度低显著相关,且结果在不同年龄、性别、种族和体重指数亚组中均具有一致性。此外,T-ALP每增加1个标准差,骨质疏松症患病率增加0.5% [比值比(95%置信区间):1.005(1.005,1.005),p < 0.001]。在骨质疏松症患者中,T-ALP每增加1个标准差,全因死亡率增加0.4% [风险比(95%置信区间):1.004(1.002,1.006),p < 0.001]。同时,将血清T-ALP水平最高(> 79 IU/L)的参与者与最低水平(< 53 IU/L)的参与者进行比较,进一步提高了骨质疏松症患病率 [比值比(95%置信区间):1.292(1.021,1.636),p = 0.033] 和全因死亡率 [风险比(95%置信区间):1.232(1.041,1.459),p = 0.015]。
基于美国成年人的代表性样本,发现血清T-ALP水平升高在所有参与者中均与骨密度降低和骨质疏松症风险增加显著相关,在骨质疏松症患者中还与全因死亡率较高有关。